An open label phase I study of ABR-215050 in patients with prostate cancer refractory to hormone therapy and with rising PSA for determination of MTD and long-term tolerability and safety ...

Researchers found that adding a newly developed modified sugar, BNAP-AEO, to gapmer antisense oligonucleotides (ASOs) increased their affinity for target RNAs, thus significantly enhancing their ...

High-Dose Melphalan With Autologous Stem-Cell Rescue in Metastatic Rhabdomyosarcoma PURPOSE: Cytarabine (ara-C) is one of the most effective chemotherapeutic agents in patients with acute leukemia (AL ...

A Japanese research team has demonstrated that the use of antisense oligonucleotides (ASOs) with modified bases and sugars can enhance the effectiveness of targeting diseases in the central nervous ...

We designed and synthesized both a conventional ASO and a ASO modified with BNAP-AEO (BNAP-AEO ASO) (top row). The ASO with BNAP-AEO exhibited a higher binding affinity to the target RNA than the ...

Diseases that affect the brain and spinal cord can be particularly devastating, and finding new and more effective ways to treat these conditions is an important goal for researchers and clinicians ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Patients with ...

ORIC Pharma's stock has nearly doubled after positive data from its second candidate, ORIC-114, which has shown a best-in-class profile. ORIC-114 has demonstrated minimal toxicity, CNS activity, and ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Encoded Therapeutics announced today the presentation of non-human primate (NHP) validation of the company’s technology to drive desired gene and protein ...